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Abstract
Purpose Women with HER2-positive breast cancer treated prior to effective anti-HER2 therapy have higher rates of local–
regional recurrence (LRR) than those with HER2-negative disease. Effective systemic therapy, however, has been shown to 
decrease LRR. This study examines LRR in women with HER2-positive breast cancer treated on a single-arm prospective 
multicenter trial of adjuvant trastuzumab (H) and paclitaxel (T).
Methods Patients with HER2-positive tumors ≤ 3.0 cm with negative axillary nodes or micrometastatic disease were eligi-
ble. Systemic therapy included weekly T and H for 12 weeks followed by continuation of H to complete 1 year. Radiation 
therapy (RT) was required following breast-conserving surgery (BCS), but dose and fields were not specified. Disease-free 
survival (DFS) and LRR-free survival were calculated using the Kaplan–Meier method.
Results Of the 410 patients enrolled from September 2007 to September 2010, 406 initiated protocol therapy and formed the 
basis of this analysis. A total of 272 (67%) had hormone receptor-positive tumors. Of 162 patients undergoing mastectomy, 
local therapy records were unavailable for two. None of the 160 for whom records were available received RT. Among 244 
BCS patients, detailed RT records were available for 217 (89%). With a median follow-up of 6.5 years, 7-year DFS was 
93.3% (95% CI 90.4–96.2), and LRR-free survival was 98.6% (95% CI 97.4–99.8).
Conclusion LRR in this select group of early-stage patients with HER2-positive disease receiving effective anti-HER2 
therapy is extremely low. If confirmed in additional studies, future investigational efforts should focus on de-escalating local 
therapy.
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Introduction
While breast cancer molecular subtype has long been 
known to impact the risk of distant disease recurrence [1], 
the relationship between subtype and risk of local regional 
recurrence (LRR) has only been more recently appreciated. 
Multiple large retrospective series in the last decade have 
shown a lower risk of LRR in women with estrogen recep-
tor-positive and progesterone receptor-positive tumors who 
are also low and intermediate grade (luminal A approxima-
tion), and higher rates of LRR in patients with both hor-
mone receptor and HER2-negative tumors, as well as those 
with HER2-positive tumors [2–4]. However, many of these 
studies included patients treated prior to the routine use of 
anti-HER2 therapy. More recently, the beneficial effects of 
effective systemic therapy on the risk of LRR have been well 
documented [5] and is likely the largest factor contributing 
to the lower risk of LRR seen in modern series. Moreover, 
this effect has been seen both with endocrine therapy and 
conventional chemotherapy, as well as with targeted agents 
[5–8]. In light of the benefits of systemic therapy on LRR 
rates, this study examines the risk of LRR in a uniform 
group of women with low-risk, HER2-positive disease, 
 * Jennifer R. Bellon
Jennifer_bellon@dfci.harvard.edu
Extended author information available on the last page of the article
receiving anti-HER2-based chemotherapy on a prospective 
single-arm trial.
Methods
Eligible patients included those with HER2-positive tumors 
(defined as 3+ staining on immunohistochemistry analysis 
and/or fluorescence in situ hybridization ratio of HER2 
to chromosome 17 centromere greater than or equal to 2) 
smaller than or equal to 3.0 cm. Patients were required to 
have a sentinel node biopsy or axillary dissection. If there 
was micrometastatic (< 0.2 mm) disease in the sentinel node, 
then a completion dissection without further nodal involve-
ment was required. Patients with macrometastatic disease in 
either the sentinel node or axillary dissection were excluded.
Systemic therapy consisted of weekly paclitaxel (T; 
80 mg/m2) and trastuzumab (H; 4 mg/kg week 1 followed by 
2 mg/kg for each subsequent week) for 12 weeks. H was con-
tinued either weekly (2 mg/kg) or every 3 weeks (6 mg/kg) 
to complete 1 year. Adjuvant endocrine therapy in patients 
with estrogen and/or progesterone receptor-positive tumors 
was encouraged, although choice of endocrine agent was left 
to the treating physician’s discretion.
Radiation therapy (RT) was mandated following breast-
conserving surgery (BCS), although the doses, target vol-
umes, and techniques were not specified. Radiation records 
were not collected as part of the core study materials. How-
ever, radiation completion notes were obtained following 
study accrual whenever possible. LRR was defined as recur-
rence in the ipsilateral breast or chest wall following breast-
conserving surgery or mastectomy, respectively, and in the 
ipsilateral infraclavicular, supraclavicular, axillary or inter-
nal mammary lymph node regions following either surgery.
Primary endpoint of the main study was invasive disease-
free survival (DFS). The null hypothesis was a 3-year event 
rate of 9.2%, and the alternate hypothesis, a 3-year event 
rate of 5% or less. This resulted in 96% probability of reject-
ing the null hypothesis. DFS and LRR-free survival were 
calculated using the Kaplan–Meier method. The present 
sub-study was designed to retrospectively analyze the risk 
of local recurrence in this uniformly treated population of 
women with HER2-positive disease receiving anti-HER2 
therapy.
Results
Patient and tumor characteristics were reported previously 
(Table 1) [9]. Patients were accrued between September 
2007 and September 2010. Four hundred and six patients 
initiated protocol therapy and form the basis of this analy-
sis. Only 36 patients (9%) had T2 (> 2.0 cm and ≤ 3.0 cm) 
primary tumors; the remaining patients had tumors 2.0 cm 
or smaller. Overall, 272 (67%) patients had estrogen and/or 
progesterone receptor-positive tumors. Most were node neg-
ative, although 6 patients (1%) had micrometastatic (2 mm 
or smaller) nodal disease.
One hundred sixty-two patients underwent mastectomy. 
None of the 160 (99% of the entire mastectomy cohort) for 
whom documentation was available received post-mastec-
tomy radiation therapy. Two hundred forty-four patients 
Table 1  Patient and treatment characteristics [9]





 < 50 132 (33)
 50–59 137 (34)
 60–69 96 (24)
 ≥ 70 41 (10)
Sex
 Female 405 (100)
 Male 1 (< 1)
Race
 White 351 (86)
 Black or African American 28 (7)
 Asian 11 (3)
 Other 16 (4)
Size of primary tumor
 T1mi (≤ 0.1 cm) 9 (2)
 T1a (0.1–≤ 0.5 cm) 68 (17)
 T1b (> 0.5–≤ 1.0 cm) 124 (31)
 T1c (> 1.0–≤ 2.0 cm) 169 (42)
 T2 (> 2.0–≤ 3.0 cm) 36 (9)
Histologic grade
 I—Well differentiated 44 (11)
 II—Moderately differentiated 131 (32)














underwent BCS. Radiation records were available for 217 
of these patients (89%). Nine of these patients (4%) were 
treated with accelerated partial breast irradiation. Two 
hundred and eight patients (96%) received radiation to the 
whole breast, and of these, 202 (97%) had additional boost 
radiation to the lumpectomy site. Among those who received 
whole breast radiation, 89% had conventional fractiona-
tion, and 11% hypofractionation (fraction size greater than 
2.5 Gy). No patient had a separate nodal field.
The current analysis includes follow-up through Novem-
ber 2016 with 2390 patient years of follow-up, and a median 
follow-up of 6.5 years. LRR-free survival at 7 years was 
98.6% (95% CI 97.4–99.8%); 99.0% (95% CI 97.7–100%) 
among BCS patients and 98.0% (95% CI 95.8–100%) among 
mastectomy patients (Fig. 1). Seven-year DFS was 93.3% 
(95% CI 90.4–96.2%); 92.1% (95% CI 88.0–96.3%) among 
BCS patients and 95.2% (95% CI 91.8–98.8%) among mas-
tectomy patients (Fig. 2).
Five patients experienced LRR as a first site of recurrence 
(3 following mastectomy, and 2 following BCS). All 3 local 
recurrences following mastectomy were in the ipsilateral 
axilla. All had undergone a negative sentinel node biopsy 
(2 patients had 0/3 sentinel nodes, 1 patient had 0/1 sentinel 
nodes). One of the patients with an axillary recurrence had 
hormone receptor-negative disease, the other 2 had hormone 
receptor-positive tumors. Two patients following BCS had 
recurrences in the ipsilateral breast. One had been treated 
with conventional fractionation to the whole breast (46.0 Gy 
in 23 fractions) followed by a 14.0 Gy lumpectomy site 
cone-down in 7 fractions. The other patient who experienced 
an ipsilateral breast recurrence had received hypofractiona-
tion to both the breast and the lumpectomy site cone down 
(42.72 Gy in 16 fractions whole breast followed by 9.0 Gy in 
3 fractions to the lumpectomy site). Both patients who had 
ipsilateral breast recurrences had hormone receptor-positive 
tumors.
Discussion
While the multiple subtypes of breast cancer, and their 
attendant impact on distant disease recurrence has long been 
appreciated [1], it is only in the last 10–15 years that the 
impact of subtype on LRR has also been described. Multi-
ple groups have demonstrated higher rates of LRR among 
women with triple-negative disease (estrogen and proges-
terone receptor-negative, HER2-negative), and HER2-pos-
itive tumors, than those with hormone receptor-positive, 
HER2-negative tumors [2–4]. For example, Nguyen et al. 
[2] in a retrospective review of 793 consecutive patients
treated with breast conservation between 1998 and 2001
found cumulative incidence of local recurrence of 0.8% for
patients with luminal A approximated tumors (defined as
estrogen receptor or progesterone receptor-positive, HER2-
negative; 95% CI 0.3–2.2) compared to 8.4% for HER2 
tumors (defined as estrogen receptor-negative, progester-
one receptor-negative, and HER2-positive; 95% CI 2.2–30), 
and 7.1% for patients with triple-negative tumors (95% CI 
3.0–16). However, these studies were largely in the era prior 
to effective anti-HER2 therapy. More recent studies have 
demonstrated low rates of LRR among women receiving 
anti-HER2 treatment. In a review of patients treated within 
the National Comprehensive Cancer Network (NCCN), 
Tseng et al. [10] found a cumulative incidence of isolated 
LRR of only 0.26% (95% CI 0.01–0.88%) for patients with 
HER2-positive disease treated with trastuzumab with a 
median follow-up of 50.1 months. Similarly, in the com-
bined National Surgical Adjuvant Breast and Bowel Project 
(NSABP) B-31 and the North Central Cancer Treatment 
Group N9831 studying trastuzumab concurrent and follow-
ing paclitaxel (T) after doxorubicin and cyclophosphamide 
(AC) compared with ACT alone, LRR as a first event was 
decreased in patients with HER2-positive disease receiving 
trastuzumab [8]. Fifty-seven patients had an isolated LRR in 
the control arm compared with 27 among those randomized 
to a trastuzumab-containing regimen. A meta-analysis of 6 
randomized trials [11] also showed a reduction in the risk 
of LRR with the addition of trastuzumab (OR  0.53, 95% CI 
0.44–0.65, p < 0.001).
The reduction in LRR with anti-HER2 therapy mimics 
a general trend of improvements in LRR with the addition 
of systemic therapy. This seems to hold true with hormonal 
therapy as well as chemotherapy [5, 7] and with increas-
ingly effective chemotherapy [6]. In the present study, which 
benefitted from a uniform patient population and systemic 
therapy regimen, the risk of LRR was exceptionally low, 
despite including patients with T2 (≤ 3 cm) and estrogen 
receptor-negative tumors. LRR at 7 years was 99.0% (95% 
CI 97.7–100%) among BCT patients and 98% (95% CI 
95.8–100%) among mastectomy patients.
This review is limited by its retrospective nature. While 
the systemic therapy was a specified component of the pro-
spective protocol, local management, including type of sur-
gery, as well as radiation fields, doses and technique were 
at the discretion of the treating physician. In addition, the 
focus on low-risk patients and resultant low rate of LRR did 
not permit identification of risk factors for recurrence that 
might guide further trials.
Future directions include prospective investigation of 
omitting radiation in women with early-stage disease under-
going breast conservation. Omission of radiation has been 
previously studied in women with small, node-negative can-
cers, and in fairly unselected women, has typically shown 
higher rates of in-breast recurrence. One representative 
study from Princess Margaret Hospital randomized 769 
women to tamoxifen alone or tamoxifen with radiation [12]. 
At 5.6 years, local recurrence was 7.7% in the tamoxifen 
alone group, and 0.6% in the women receiving tamoxifen 
and radiation (hazard ratio 8.3; 95% CI 3.3–21.2, p < 0.001). 
However, when the authors retrospectively looked back 
at a subset of women for whom immunohistochemical 
biomarkers permitted an approximation of intrinsic sub-
type, the benefit of radiation in women with luminal A 
approximation was numerically modest and not statis-
tically significant (3.3% vs. 7.3% at 10 years, p = 0.11) 
[13]. Several studies are currently enrolling patients with 
Fig. 1  a Local–regional 
recurrence-free survival among 
breast conservation patients. b 
Local–regional recurrence-free 
survival among mastectomy 
patients
putative low-risk estrogen receptor-positive, HER2-negative 
tumors in prospective trials utilizing hormonal therapy in 
lieu of adjuvant radiation following breast-conservation. 
Low-risk patients are identified by either PAM50 (PRE-
CISION, NCT02653755; EXPERT, NCT02889874), 
OncotypeDX (IDEA, NCT02400190) or Ki67 (LUMINA, 
NCT01791829). Similarly, early-stage patients receiving 
effective anti-HER2 therapy may also be appropriate for 
protocol-based study of the omission of radiation, due to 
their low rate of local recurrence with radiation. Despite 
 
Fig. 2  a Disease-free survival 
among breast-conservation 
patients. b Disease-free survival 
among mastectomy patients
recent efforts to improve the safety of radiation therapy, it 
is inconvenient, and associated with both acute and chronic 
moribidity, as well as a small risk of second malignancy. 
Identifying women in whom radiation therapy can safely 
be omitted is an important effort in improving quality of 
life and decreasing treatment-related complications. While 
hormone receptor-positive, HER2-positive patients are 
particularly attractive candidates for such an approach, as 
they are also appropriate recipients of hormonal therapy, 
the present study showed equally low rates of LRR in both 
hormone receptor-positive and hormone receptor-negative 
tumors, suggesting that perhaps small anatomic size alone 
may be an adequate selection factor in this population.
Other opportunities for investigation include omission of 
nodal radiation in patients with HER2-positive tumors and 
involved axillary lymph nodes following BCS, and similarly 
omission of post-mastectomy radiation therapy in women 
with HER2-positive disease and 1–3 axillary nodes. In the 
era prior to HER2-directed therapy, the risk of regional 
recurrences and recurrences following mastectomy were 
higher in women with HER2-positive disease. Voduc et al. 
[4] retrospectively studied the impact of approximated bio-
logic subtype in 2985 patients with non-metastatic breast
cancer undergoing primary breast surgery in the era prior
to anti-HER2 therapy. In the breast conservation cohort,
10-year risk of regional recurrence was 3% among patients
with luminal A tumors compared to 16% in those with
HER2-enriched disease. Similarly, the risk of both chest
wall and regional nodal recurrences was elevated in mastec-
tomy patients with HER-enriched tumors compared to those
with luminal A disease. Moreover, randomized trials have
shown a DFS benefit to supraclavicular and internal mam-
mary radiation in women with node-positive and high-risk
node-negative disease. These studies, however, predated the
routine use of anti-HER2 therapy [14, 15]. Although only
a minority of the patients on the present study had involved
axillary nodes (micrometastasis only), the very low rate of
LRR suggests that that omission of nodal RT in the BCS set-
ting, and omission of RT altogether following mastectomy in
women with limited nodal involvement, may be reasonable
avenues for further study.
Prior to effective systemic therapy, potential improve-
ments in survival with aggressive local therapy were largely 
overshadowed by distant metastases. This was likely the case 
in the landmark NSABP B-04 study [16], where there was 
no difference in survival between patients randomized to 
radical mastectomy, total mastectomy with adjuvant radia-
tion, and total mastectomy with neither dissection nor axil-
lary radiation. Distant DFS was low in both groups (38–46% 
at 25 years, without differences between the arms). However, 
as the ability to control microscopic metastases increased 
with gains in systemic therapy, improvements in local con-
trol translated into decreases in distant metastases and better 
overall survival [17]. This was seen in both the Danish post-
mastectomy trials (82b and 82c) [18, 19]. It is conceivable 
that in very select patients with HER2-positive breast cancer, 
systemic therapy is now sufficient treatment for both local 
as well as distant disease, potentially permitting safe de-
escalation of local therapy [20] and should be investigated 
in future studies.
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